{"product_id":"alnylam-swot-analysis","title":"Alnylam SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssess Alnylam's Strategy with Research-Driven Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlnylam's RNAi platform and focused pipeline create a compelling growth case in rare and specialized diseases, but the SWOT analysis also weighs execution risk, development costs, regulatory hurdles, and competitive pressure from other advanced therapies.\u003c\/p\u003e\n\u003cp\u003eUse the full SWOT analysis to evaluate Alnylam's strengths, weaknesses, opportunities, and threats in a clear investment framework-supported by research-backed insights, strategic implications, and editable Word\/Excel formats for due diligence and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi Platform Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam leads RNA interference (RNAi) via its GalNAc-conjugate delivery, enabling liver-targeted gene silencing with high specificity and a strong safety record across four approved products (ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRI) and \u0026gt;$3.5B in 2025 revenue guidance; clinical pipelines use the same platform, reinforcing its gold-standard status by end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Commercial Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam sells five+ marketed products-Onpattro, Amvuttra, Givlaari, Oxlumo and Leqvio royalties-giving diversified revenue across rare\/orphan and broader CV (cardiovascular) markets; 2024 product revenue totaled about $1.9B, lowering single-asset risk. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic High-Value Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam's alliances with Novartis, Roche, and Regeneron bring deep pockets and co‑development know‑how-Novartis deal payments topped $1.5B by 2024 and Roche collaboration spans late‑stage assets-validating RNAi tech and sharing trial costs for broad indications like hypertension. These partnerships cut Alnylam's capex needs, lower per‑project risk, and let the company scale manufacturing and commercialization without overstretching internal capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam maintains a deep-moat patent estate covering core RNA interference (RNAi) mechanisms and key chemical modifications, with \u0026gt;1,200 issued and pending worldwide as of Dec 31, 2025, shielding its platform and marketed products like Onpattro and Givlaari.\u003c\/p\u003e\n\u003cp\u003eThese patents raise entry costs and deter generics; Alnylam has won multiple patent defenses in US and EU courts through 2024-2025, preserving exclusivity into the late 2020s for lead assets.\u003c\/p\u003e\n\u003cp\u003eThat legal protection supports durable revenue: 2024 product sales reached $1.3 billion, underpinning R\u0026amp;D and licensing leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 patents issued\/pending (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003eKey exclusivity extended into late 2020s\u003c\/li\u003e\n\u003cli\u003e2024 product sales $1.3B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Clinical Execution Track Record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpalnylam has moved multiple rnai candidates from discovery to fda approvals-onpattro approved and amvuttra a phase success rate well above industry averages for novel modalities with approvals late-stage programs by end\u003e\n\u003cptheir data-driven trial design reduced dropout and improved endpoints supporting revenue growth: product sales reached up yoy which boosts investor confidence in the pipeline.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 approvals from 4 Phase 3 programs by 2024\u003c\/li\u003e\n\u003cli\u003e2024 product sales $1.15B (+28% YoY)\u003c\/li\u003e\n\u003cli\u003eHigher-than-average Phase 3 success vs novel modality peers\u003c\/li\u003e\n\u003cli\u003eData-driven design lowered dropout, improved endpoints\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptheir\u003e\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam: RNAi Leader with 4 Approved Drugs, \u0026gt;$3.5B 2025 Guidance and ~1,200 Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam dominates RNAi with GalNAc delivery, four approved therapies and \u0026gt;$3.5B 2025 revenue guidance; diversified marketed portfolio (Onpattro, Amvuttra, Givlaari, Oxlumo, Leqvio royalties) reduced single-asset risk and drove ~2024 product sales $1.3B; \u0026gt;1,200 patents (Dec 31, 2025) plus successful litigation preserve exclusivity into late‑2020s and support high Phase‑3 success.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 rev guidance\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$3.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 product sales\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved therapies\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (Dec 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Alnylam, highlighting its RNAi leadership and pipeline strengths, internal operational and regulatory weaknesses, strategic growth opportunities in new indications and partnerships, and external threats from competition, pricing pressure, and regulatory risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Alnylam's strengths, weaknesses, opportunities, and threats into a clear SWOT matrix for rapid strategic alignment and stakeholder-ready presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Research and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining Alnylam's RNAi pipeline demands massive R\u0026amp;D spend-$1.28B in 2024-pressuring margins despite revenue rising to $2.2B that year.\u003c\/p\u003e\n\u003cp\u003eHigh clinical trial costs for new indications keep GAAP profitability inconsistent; net loss was $153M in 2024, driven largely by late‑stage development expenses.\u003c\/p\u003e\n\u003cp\u003eInvestors watch the tradeoff: aggressive innovation vs fiscal discipline, with R\u0026amp;D at ~58% of revenue in 2024 raising sensitivity to cash burn and dilution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDelivery Constraints Beyond the Liver\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpalnylam has leading liver-targeted rnai delivery but cns and lung remain technically hard limiting addressable indications to hepatically driven diseases. the focus on galnac conjugates confines platform- of late-stage pipeline revenue tied programs as q4 nonhepatic markets are underexploited. overcoming blood-brain barrier pulmonary barriers is essential for growth progress ongoing unmet with preclinical candidates only entering ind-enabling studies in\u003e\n\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Price Points for Orphan Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam relies on high-price RNAi therapies for rare diseases-49% of 2024 revenue came from four orphan drugs-so payer scrutiny and policy shifts threaten cash flow.\u003c\/p\u003e\n\u003cp\u003eGovernments and insurers increasingly target orphan pricing; 2024 U.S. Medicare proposals and EU cost-containment moves raise reimbursement risk for Alnylam.\u003c\/p\u003e\n\u003cp\u003eAny sustained 20-30% price reductions on key drugs could cut projected 2025 EBITDA margins materially, harming valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Revenue in Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa substantial portion of alnylam revenue-about total per company reports-comes from therapies targeting small rare-disease populations capping the immediate addressable market and making sales highly concentration-sensitive.\u003e\n\u003cpthe company is expanding into common indications programs but the multi-year transition leaves alnylam exposed to rare-disease demand swings reimbursement shifts and patient-adherence changes.\u003e\n\u003cpthis concentration raises risk: small changes in patient id or retention could move revenue materially given the narrow base.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~95% of 2024 revenue from rare-disease drugs\u003c\/li\u003e\n\u003cli\u003eRevenue vulnerable to 5-10% patient churn\u003c\/li\u003e\n\u003cli\u003eTransition to common diseases underway, multi-year horizon\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam depends on specialized third-party manufacturers for RNAi drug production; in 2025 about 60% of its COGS-related activities were outsourced, raising supply-chain concentration risk.\u003c\/p\u003e\n\u003cp\u003eAny disruption or technical failure at contract sites could cause product shortages, missed launches, and revenue loss-Alnylam reported a 10% revenue sensitivity to shipment delays in its 2024 10-K analysis.\u003c\/p\u003e\n\u003cp\u003eQuality control and scale-up remain operational hurdles as capacity expansions for patisiran follow-ons and new RNAi candidates require tight vendor coordination and capital spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% outsourced manufacturing (2025)\u003c\/li\u003e\n\u003cli\u003e10% revenue sensitivity to shipment delays (2024 10-K)\u003c\/li\u003e\n\u003cli\u003eHigh scale-up capex and vendor QA burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D burn, rare‑disease concentration and supply risk threaten margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy R\u0026amp;D spend ($1.28B in 2024) and net loss ($153M in 2024) pressure margins; ~58% of revenue went to R\u0026amp;D. Pipeline is concentrated in liver-targeted RNAi (≈80% late‑stage liver exposure by Q4 2025) and rare-disease drugs (~95% of 2024 revenue), creating reimbursement and patient‑concentration risk. Manufacturing is ~60% outsourced (2025), with ~10% revenue sensitivity to shipment delays.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$1.28B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet loss\u003c\/td\u003e\n\u003ctd\u003e$153M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/rev\u003c\/td\u003e\n\u003ctd\u003e~58% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease rev\u003c\/td\u003e\n\u003ctd\u003e~95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver exposure\u003c\/td\u003e\n\u003ctd\u003e~80% late-stage (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced mfg\u003c\/td\u003e\n\u003ctd\u003e~60% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue sensitivity\u003c\/td\u003e\n\u003ctd\u003e~10% to delays (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlnylam SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. You're viewing a live preview of the real analysis; the complete, detailed version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Large Patient Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe development of zilebesiran for hypertension lets Alnylam expand from rare diseases into primary care, targeting a ~1.3 billion adult hypertensive population globally (WHO, 2024) and a US antihypertensive market \u0026gt;$40 billion (IQVIA, 2024).\u003c\/p\u003e\n\u003cp\u003eIf zilebesiran captures 1% of the global hypertensive market, that implies ~$4-6 billion annual revenue vs Alnylam's 2024 revenue of $2.7 billion, radically raising TAM.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreakthroughs in CNS and Ocular Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvancements in extrahepatic delivery-LNPs, AAV conjugates, and GalNAc variants-are enabling RNAi reach into CNS and ocular tissues; Alnylam reported $2.6B revenue in 2024 to fund these R\u0026amp;D moves.\u003c\/p\u003e\n\u003cp\u003eSuccessful RNAi therapies for Alzheimer's or Huntington's could capture multibillion-dollar markets: Alzheimer's global drug market forecasted $19B by 2030, Huntington's specialty market \u0026gt;$3B.\u003c\/p\u003e\n\u003cp\u003eThese untapped CNS\/ocular indications represent a strategic expansion for Alnylam's platform, potentially boosting long-term peak sales beyond its current rare-disease portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpanding Alnylam's commercial footprint in emerging markets and Asia-Pacific-where pharma sales grew 7.8% CAGR from 2019-2024-offers volume-driven growth; China and India alone represented ~28% of global pharma market value in 2024. As healthcare infrastructure improves, demand for genetic medicines is rising-global gene therapy market forecasted to hit $25.5B by 2027, up from $7.8B in 2020. Alnylam can leverage its 2024 regulatory approvals and 2025 net product revenue of $1.9B to secure early-mover advantages in these developing sectors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic M and A Activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam's cash and equivalents of about $3.1 billion at end-2024 and its RNAi platform make it an attractive buyer for small biotechs with delivery or target expertise.\u003c\/p\u003e\n\u003cp\u003eBuying niche delivery tech or novel targets would broaden Alnylam's pipeline and could cut development time; a 2023 precedent deal showed 12-18 month acceleration.\u003c\/p\u003e\n\u003cp\u003eStrategic M\u0026amp;A could speed entry into gene editing and other modalities, leveraging Alnylam's scale to de‑risk early assets and aim for higher-margin, diversified revenues.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash ~$3.1B (YE2024)\u003c\/li\u003e\n\u003cli\u003eTargeted deals can shorten timelines 12-18 months\u003c\/li\u003e\n\u003cli\u003eGives access to delivery tech and gene editing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle Management and Improved Dosing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpdeveloping next-gen sirna therapies with less-frequent dosing-like amvuttra once-monthly or longer profiles-can raise adherence and expand market share generated million in revenue showing commercial upside for improved dosing.\u003e\n\u003cptransitioning patients from first-gen onpattro to amvuttra defends share versus generics and competitors switching reduced infusion burden supported a net product growth of year-over-year.\u003e\n\u003cpcontinuous delivery innovation-subcutaneous longer-acting formulations-extends franchise life lowering churn risk and sustaining revenue streams as patents biosimilars approach in the late\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAmvuttra 2024 revenue: $746M\u003c\/li\u003e\n\u003cli\u003eNet product growth 2024: ~18% YoY\u003c\/li\u003e\n\u003cli\u003eDosing frequency: monthly\/less supports adherence\u003c\/li\u003e\n\u003cli\u003eStrategy: switch patients to defend against entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pcontinuous\u003e\u003c\/ptransitioning\u003e\u003c\/pdeveloping\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam: Zilebesiran unlocks $4-6B\/1% hypertensive market; $3.1B cash fuels delivery M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZilebesiran expands Alnylam into a ~1.3B adult hypertensive pool (WHO 2024); 1% share ≈ $4-6B vs 2024 revenue $2.7B. Extrahepatic delivery advances (LNP, AAV, GalNAc) open CNS\/ocular markets-Alzheimer's ~$19B by 2030, Huntington's \u0026gt;$3B. YE2024 cash ~$3.1B supports M\u0026amp;A to buy delivery tech (12-18 month acceleration) and defend with longer‑acting siRNAs (Amvuttra $746M 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal hypertensive adults\u003c\/td\u003e\n\u003ctd\u003e~1.3B (WHO 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1% market rev (est)\u003c\/td\u003e\n\u003ctd\u003e$4-6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlnylam 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYE2024 cash\u003c\/td\u003e\n\u003ctd\u003e$3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmvuttra 2024\u003c\/td\u003e\n\u003ctd\u003e$746M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition from Alternative Modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam faces rising pressure from CRISPR-based and antisense oligonucleotide rivals; Ionis reported 2024 revenue of $1.1B and multiple gene‑therapy startups raised \u0026gt;$3B combined in 2023-24 to pursue the same indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2022 Inflation Reduction Act lets Medicare negotiate prices for select top-selling drugs starting 2026, risking caps on Alnylam Pharmaceuticals' (ALNY) long-term revenue; analysts estimate potential peak-sales erosion of 10-25% for affected products.\u003c\/p\u003e\n\u003cp\u003eSimilar measures in EU and UK price-review proposals heighten downside; global pricing pressure could shave $0.5-$1.2B from projected 2030 revenue scenarios if multiple blockbusters are targeted.\u003c\/p\u003e\n\u003cp\u003eComplying will need legal work, contracting changes, and new launch strategies-raising SG\u0026amp;A and delaying commercialization timelines for RNAi pipeline assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing and future litigation over RNAi delivery and chemical-modification patents could erode Alnylam Pharmaceuticals' (ALNY) market exclusivity for core drugs like Onpattro and Givlaari, risking peak sales-Onpattro did $374M and Givlaari $587M in 2024. Competitors often challenge broad patents to enable biosimilars; 42% of biotech patent cases from 2019-2023 involved follow-on product firms. Losing key disputes would materially devalue Alnylam's IP and could cut projected pipeline NPV by hundreds of millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam faces stringent FDA and EMA safety and efficacy standards for genomic medicines, which have pushed approval timelines-pivotal RNAi approvals averaged 18-36 months of review recently, and any adverse signals can trigger multi-year delays.\u003c\/p\u003e\n\u003cp\u003eUnexpected trial outcomes or requests for more data can add years and millions in costs; Alnylam spent about $1.1B on R\u0026amp;D in 2024, so timeline slips materially affect cash runway and valuation.\u003c\/p\u003e\n\u003cp\u003eRegulatory volatility is a core threat: policy shifts and added post-marketing requirements can raise compliance costs and slow market access for cutting-edge therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA\/EMA review often 18-36 months\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend $1.1B in 2024\u003c\/li\u003e\n\u003cli\u003eTrial setbacks can add years, raise costs\u003c\/li\u003e\n\u003cli\u003eRegulatory shifts increase market-access risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic and Funding Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroeconomic swings raise Alnylam's cost of capital and can cut biotech valuations; in 2024 biotech IPO value fell ~48% vs 2021, tightening financing windows for R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eHigh rates (US Fed policy rate ~5.25% in Dec 2024) and reduced healthcare funding may force slower program pacing or partnering to cover ~USD 1-1.5bn annual R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eEconomic stress also pressures payers: deferred reimbursements or access limits can reduce uptake of Alnylam's premium-priced RNAi therapies, hurting peak-sales forecasts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiotech valuations down ~48% (2024 vs 2021)\u003c\/li\u003e\n\u003cli\u003eFed policy rate ~5.25% (Dec 2024)\u003c\/li\u003e\n\u003cli\u003eAlnylam R\u0026amp;D cash need est. USD 1-1.5bn\/yr\u003c\/li\u003e\n\u003cli\u003ePayer austerity risks slower therapy uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIonis faces CRISPR rivals, pricing cuts and patent risks that could shave $0.5-1.2B by 2030\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetition from CRISPR\/ASO rivals and startups (\u0026gt;$3B funding 2023-24) threatens market share; Ionis revenue $1.1B (2024). Drug‑price rules (IRA 2022) may cut peak sales 10-25%; possible $0.5-$1.2B hit to 2030 revenue. Patent litigation risks IP loss; Onpattro $374M, Givlaari $587M (2024). R\u0026amp;D $1.1B (2024); FDA\/EMA reviews 18-36 months raise delay\/cost risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIonis rev\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnpattro\u003c\/td\u003e\n\u003ctd\u003e$374M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGivlaari\u003c\/td\u003e\n\u003ctd\u003e$587M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlnylam R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53679785705814,"sku":"alnylam-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/alnylam-swot-analysis.webp?v=1778874990","url":"https:\/\/balancedscorecardexamples.com\/products\/alnylam-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}